Sofinno­va Telethon Fund backs Nal­dini's gene ther­a­py biotech; ORIC prices $75M IPO

→ The Sofinno­va Telethon Fund has found a new gene ther­a­py up­start to back. The fund se­lect­ed Gene­spire for its port­fo­lio, tap­ping a biotech in­spired …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.